https://www.selleckchem.com/pr....oducts/LY2784544.htm
Currently, the immunotherapy approved for gastric cancer is immune checkpoint blockade( IC therapy. The effects of ICB depend on the T cell-mediated immune response elicited at the cancer site. Based on the results of previous clinical trials, it is clear that an enhanced immune response to cancer improves prognosis. Thus, the development of biomarkers to predict local immune responses may increase the significance of future immunotherapy for gastric cancer. Biomarker research has clearly progressed with the rapid development of gen
Like
Comment
Share
